Jamy D. Ard

Historically, obesity was viewed as a lifestyle disease, with an associated lifestyle solution, and approaches that embody the “eat less, move more” idea have dominated obesity treatment recommendations for over half a century. Meanwhile, the prevalence and severity of obesity continue to increase globally. Enter the so‐called “game changers”: glucagon‐like peptide‐1 receptor agonists. In the media frenzy around these and other new antiobesity medications in the pipeline, lifestyle‐based treatment researchers and practitioners may find themselves wondering whether behavioral approaches to obesity will become obsolete in this new therapeutic era. In this Perspective, the authors contend that medical approaches impact physiologic pathways to support the success of behavioral approaches. Similarly, behavioral approaches can improve weight loss‐adjacent outcomes that are not addressed by medication. Thus, the two approaches are complementary and must coexist if we are to make a significant, population‐level impact on the obesity epidemic.